Sleep Apnea Pill Slashes Symptoms 44% in Trials

The phase 2 trial enrolled 200 patients with moderate-to-severe obstructive sleep apnea. Participants taking the pill experienced a 44% reduction in the apnea-hypopnea index, the standard measure of symptom severity. This rivals the efficacy of CPAP for many patients.

Current CPAP machines have a 50% non-adherence rate within the first year. The pill addresses this compliance gap by requiring no nightly setup or mask. Pharmaceutical companies are racing to capitalize on this unmet need.

If approved, the drug could disrupt a CPAP market valued at $8 billion. ResMed and Philips face an existential threat as patients seek simpler solutions. The FDA has granted breakthrough therapy designation, accelerating the approval timeline.

Power Move: This pill doesn't just treat sleep apnea—it rewrites the standard of care. CPAP manufacturers must innovate or watch their market evaporate. The next frontier: combining this drug with wearable diagnostics for personalized therapy.

This article was edited with AI assistance for readability. Read original here.